Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹128.60
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.16B
Enterprise Value₹2.46B
Total Cash (Recent Filing)₹11.89M
Total Debt (Recent Filing)₹316.57M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.58
Price to Sales (P/S)2.64
P/FCF Ratio-26.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Improving MarginsSustained top-line growth alongside rising EBIT/EBITDA margins indicates improving operational efficiency and pricing or mix gains. That combination supports durable earnings power, allowing reinvestment into capacity and product development over the coming several quarters.
Improving Balance-sheet Metrics And Reduced LeverageA stronger equity ratio and lower debt-to-equity reduce financial fragility and interest burden, improving the company's resilience to shocks. This enhances flexibility for capex or working-capital needs and lowers refinancing risk over the medium term.
Diversified Pharma Business Model (APIs And Formulations, Domestic And Export)A dual-focus on finished formulations and APIs across domestic and export channels creates multiple revenue streams and customer relationships. This structural diversification mitigates demand swings in specific segments and supports durable revenue scaling and margin optimization.
Bears Say
Weak Cash Generation And Negative Free Cash FlowNegative free cash flow and low cash conversion of profits constrain the company's ability to self-fund expansion, approvals or working-capital needs. Continued capex-driven outflows may force external financing or delay strategic investments in the next several quarters.
Overall Liabilities Remain HighPersistently high absolute liabilities elevate refinancing and interest-rate exposure, limiting financial flexibility. Even with improved ratios, elevated liabilities can pressure liquidity during operational slowdowns or if cash generation stays weak over the coming months.
Large Negative EPS Growth And Earnings VolatilitySubstantial negative EPS growth signals earnings volatility or one-off impacts that undermine predictability of profits. That variability complicates planning, weakens internal capital allocation confidence and raises execution risk for sustaining margin improvements.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹128.60 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.16B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Jun 02, 2026 which is in 32 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on Jan 29, 2026. The company reported ₹0 earnings per share for the quarter, the consensus estimate of N/A by ₹0.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 35,690,000 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of ₹0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.741%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―